ANTERIS TEC.GLO. DL-,0001

Anteris Technologies Global has appointed Susan Knight and Stephen Denaro to its board; the appointments took effect in the US and Australia, respectively, earlier this week. Knight was appointed as a Class I director until the 2028 AGM and will serve on the audit and risk committee; Denaro was appointed as a Class II director until the 2026 AGM. On appointment, Knight receives RSUs worth USD 250,000 and is eligible for annual equity grants worth USD 125,000; Denaro may also be eligible for the annual grant and receives AUD 57,645 in remuneration for his role as company secretary. Both agreements include Delaware-law indemnification provisions, according to an SEC filing. » More on de.investing.com

Anteris has begun the global approval-relevant PARADIGM study in the US for the DurAVR transcatheter heart valve and has treated the first patients. The prospective, randomized and controlled trial will randomize about 1,000 patients 1:1 to DurAVR versus commercially available THVs and will test non-inferiority for mortality, strokes and cardiovascular hospitalizations at one year. The DurAVR is a balloon-expandable valve with ADAPT anti-calcification technology, which Anteris says has already been used in more than 55,000 patients; the stock rose 46% over the past six months. » More on de.investing.com

Anteris Technologies has terminated its obligation to make further development contributions under the agreement with v2vmedtech and is paying a contractual penalty of $400,000. Payment of the penalty also ends the related development agreement and releases Anteris from any further contribution payments. The existing shareholders of v2vmedtech can either acquire Anteris’ entire stake at the prior contribution price or reduce the stake to an agreed minority holding; v2vmedtech has not yet informed its choice. Anteris expects no material adverse impact on its consolidated financial position or liquidity. » More on de.investing.com